Our results demonstrate that similar aortic modifications occur within the given Ang II dose range concomitantly with progression of hypertrophy and diastolic dysfunction in both hypertensive groups, indicating that this mouse model could be further utilized to investigate the related molecular mechanisms and therapeutic approaches for hypertension, diastolic dysfunction, and early HFpEF interventions. The gene discussed is AGT; the disease is Hypertension.